Bayer's Regorafenib Gains Orphan Drug Status

Bayer's investigational compound regorafenib has been granted orphan drug status by FDA for the treatment of patients with gastrointestinal stromal tumours.

Bayer HealthCare Pharmaceuticals announced that its investigational anti-cancer compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by FDA.

"Despite treatment advances over the past several years, GIST remains a potentially fatal disease, and there is still a significant unmet medical need for additional treatment options for the majority of patients," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee. "This is an important step in the overall development process for this investigational compound."

In January, Bayer announced that the